COMT and breast adenocarcinoma: In this communication, we describe a cell-based system to assess estrogenic agents, which utilizes a novel competitive ELISA, based on exclusive expression of soluble-form catechol-O-methyltransferase (S-COMT) isoform in a ER-positive human breast adenocarcinoma MCF-7 cell line [19].